Vemlidy’s active competition in chronic hepatitis B treatment market

Gilead Sciences’ ‘Vemlidy Tab’ has entered general hospitals one after another, which raises an expectation on its sales performance in the future.

‘Vemlidy,’ a Gilead Sciences’ chronic hepatitis B treatment whose health insurance benefit has started to be applied on both first and resistance patients from the 1^st, has consecutively entered Severance Hospital and Samsung Medical Center recentl...